一项前瞻性研究:比较99mTc-羟基亚乙基二膦酸盐平面骨显像与全身SPECT/CT及18F-氟化钠PET/CT和18F-氟化钠PET/MRI诊断骨转移
前瞻性纳入117例组织学证实恶性肿瘤并转诊行临床平面骨显像的患者,比较99mTc-HDP平面骨显像、SPECT/CT、18F-NaF PET/CT及PET/MRI(46例)诊断骨转移。骨转移确认16例、排除101例,患病率14%低于预期。平面骨显像可疑判读显著多于SPECT/CT和PET/CT,但排除可疑判读后各技术灵敏度、特异度、阳性预测值、阴性预测值及总准确率无统计学显著差异。
要点
- 平面骨显像可疑判读数显著高于SPECT/CT和PET/CT(18 vs 5和6,P=0.004和0.01)。
- 排除可疑判读后各影像技术灵敏度、特异度、阳性预测值、阴性预测值及总准确率无统计学显著差异。
- 在参考标准确认骨转移的患者中,SPECT/CT、PET/CT、PET/MRI较平面骨显像分别额外检出31%、63%、71%的病灶。
核心结论
- 18F-NaF PET/CT和全身SPECT/CT较平面骨显像显著减少可疑判读,意味着诊断信心提高。
- 在该骨转移患病率相对较低(14%)的人群中,使用18F-NaF PET/CT或PET/MRI相较SPECT/CT和平面骨显像的临床获益可能有限。
- 该结论受骨转移患者低患病率影响;SPECT/CT、PET/CT和PET/MRI相较平面骨显像的灵敏度可能存在显著差异,但需研究更大样本或骨转移患病率更高的人群方能证实。
研究设计与样本
- 前瞻性纳入117例组织学证实恶性肿瘤并转诊行临床平面骨显像的患者。
- 行平面骨显像和全身SPECT/CT后9天内行18F-NaF PET/CT,其中46例另行18F-NaF PET/MRI。
主要发现
- 骨转移确认16例、排除101例,低于预期。
- 可疑扫描数平面骨显像显著高于SPECT/CT和PET/CT(18 vs 5和6;P=0.004和0.01)。
- 排除可疑判读后,各影像技术间灵敏度、特异度、阳性预测值、阴性预测值及总准确率均无统计学显著差异。
- 悲观分析(可疑判读假定为转移阳性)误诊患者百分比:平面骨显像21%、SPECT/CT 15%、PET/CT 9%、PET/MRI 7%。
- 乐观分析(可疑判读假定为转移阴性)误诊患者百分比:平面骨显像9%、SPECT/CT 12%、PET/CT 5%、PET/MRI 7%。
局限性
- 骨转移患病率相对较低(14%),低于预期,影响结论。
- 需研究更大样本或骨转移患病率更高的人群方能证实SPECT/CT、PET/CT和PET/MRI相较平面骨显像的灵敏度差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We prospectively evaluated and compared the diagnostic performance of 99mTc-hydroxyethylene-diphosphonate (99mTc-HDP) planar bone scintigraphy (pBS), 99mTc-HDP SPECT/CT, 18F-NaF PET/CT, and 18F-NaF PET/MRI for the detection of bone metastases. Methods: One hundred seventeen patients with histologically proven malignancy referred for clinical pBS were prospectively enrolled. pBS and whole-body SPECT/CT were performed followed by 18F-NaF PET/CT within 9 d. 18F-NaF PET/MRI was also performed in 46 patients. Results: Bone metastases were confirmed in 16 patients and excluded in 101, which was lower than expected. The number of equivocal scans was significantly higher for pBS than for SPECT/CT and PET/CT (18 vs. 5 and 6, respectively; P = 0.004 and 0.01, respectively). When equivocal readings were excluded, no statistically significant difference in sensitivity, specificity, positive predictive value, negative predictive value, or overall accuracy were found when comparing the different imaging techniques. In the per-patient analysis, equivocal scans were either assumed positive for metastases ("pessimistic analysis") or assumed negative for metastases ("optimistic analysis"). The percentages of misdiagnosed patients for the pessimistic analysis were 21%, 15%, 9%, and 7% for pBS, SPECT/CT, PET/CT, and PET/MRI, respectively. Corresponding figures for the optimistic analysis were 9%, 12%, 5%, and 7%. In those patients identified as having bone metastases according to the reference standard, SPECT/CT, 18F-NaF PET/CT, and PET/MRI detected additional lesions compared with pBS in 31%, 63%, and 71%, respectively. Conclusion:18F-NaF PET/CT and whole-body SPECT/CT resulted in a significant reduction of equivocal readings compared with pBS, which implies an improved diagnostic confidence. However, the clinical benefit of using, for example, 18F-NaF PET/CT or PET/MRI as compared with SPECT/CT and pBS in this patient population with a relatively low prevalence of bone metastases (14%) is likely limited. This conclusion is influenced by the low prevalence of patients with osseous metastases. There may well be significant differences in the sensitivity of SPECT/CT, PET/CT, and PET/MRI compared with pBS, but a larger patient population or a patient population with a higher prevalence of bone metastases would have to be studied to demonstrate this.
引用
- Löfgren J, Mortensen J, Rasmussen SH, et al. A Prospective Study Comparing 99mTc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with 18F-Fluoride PET/CT and 18F-Fluoride PET/MRI for Diagnosing Bone Metastases. J Nucl Med. 2017. PMID: 28798033. doi:10.2967/jnumed.116.189183
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。